AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Perspectives
This section features opinion pieces, reflections, and expert commentary on timely or overlooked issues in cancer care, research, and the oncology workforce.
Immunotherapy Is Moving Earlier Into Head and Neck Cancer Treatment
By Hyunseok Kang, MD, MPH
Head and neck cancer treatment has historically advanced roughly once a decade, but two meaningful updates are arriving together this year
Immunotherapy Is Moving Earlier Into Head and Neck Cancer Treatment
By Hyunseok Kang, MD, MPH
Head and neck cancer treatment has historically advanced roughly once a decade, but two meaningful updates are arriving together this year
Immunotherapy Is Moving Earlier Into Head and Neck Cancer Treatment
By Hyunseok Kang, MD, MPH
Head and neck cancer treatment has historically advanced roughly once a decade, but two meaningful updates are arriving together this year
MDS, MECOM-Rearranged Leukemia, and BPDCN: New Data Reshaping Treatment Choices
By Cecilia Arana Yi, MD
The VERONA trial finds venetoclax adds no survival benefit in higher-risk MDS; new data illuminate outcomes in MECOM-rearranged AML and BPDCN, where transplant remains the strongest predictor of survival.
MDS, MECOM-Rearranged Leukemia, and BPDCN: New Data Reshaping Treatment Choices
By Cecilia Arana Yi, MD
The VERONA trial finds venetoclax adds no survival benefit in higher-risk MDS; new data illuminate outcomes in MECOM-rearranged AML and BPDCN, where transplant remains the strongest predictor of survival.
MDS, MECOM-Rearranged Leukemia, and BPDCN: New Data Reshaping Treatment Choices
By Cecilia Arana Yi, MD
The VERONA trial finds venetoclax adds no survival benefit in higher-risk MDS; new data illuminate outcomes in MECOM-rearranged AML and BPDCN, where transplant remains the strongest predictor of survival.
Overcoming Language Barriers in Cancer Care
By Kaila Johnson
Language barriers delay cancer diagnoses and lower screening rates for patients with limited English proficiency. Experts weigh in on interpreter access, cultural competence, and why closing these gaps is critical to equitable cancer care.
Overcoming Language Barriers in Cancer Care
By Kaila Johnson
Language barriers delay cancer diagnoses and lower screening rates for patients with limited English proficiency. Experts weigh in on interpreter access, cultural competence, and why closing these gaps is critical to equitable cancer care.
Overcoming Language Barriers in Cancer Care
By Kaila Johnson
Language barriers delay cancer diagnoses and lower screening rates for patients with limited English proficiency. Experts weigh in on interpreter access, cultural competence, and why closing these gaps is critical to equitable cancer care.
The First Positive Phase 3 Trial Ever in Dedifferentiated Liposarcoma Changes a Difficult Conversation
By David Savage, MD
Dedifferentiated liposarcoma has had no positive phase 3 trial in its history, and existing chemotherapy options rarely delay progression beyond a few months.
The First Positive Phase 3 Trial Ever in Dedifferentiated Liposarcoma Changes a Difficult Conversation
By David Savage, MD
Dedifferentiated liposarcoma has had no positive phase 3 trial in its history, and existing chemotherapy options rarely delay progression beyond a few months.
The First Positive Phase 3 Trial Ever in Dedifferentiated Liposarcoma Changes a Difficult Conversation
By David Savage, MD
Dedifferentiated liposarcoma has had no positive phase 3 trial in its history, and existing chemotherapy options rarely delay progression beyond a few months.
Will Multispecific CAR T-Cell Therapy Replace Single-Target CD19 Treatment in Lymphoma?
By Saurabh Dahiya, MD, FACP
CD19-directed CAR T-cell therapy has transformed care for B-cell lymphomas, but most patients still relapse, often due to loss of the CD19 target.
Will Multispecific CAR T-Cell Therapy Replace Single-Target CD19 Treatment in Lymphoma?
By Saurabh Dahiya, MD, FACP
CD19-directed CAR T-cell therapy has transformed care for B-cell lymphomas, but most patients still relapse, often due to loss of the CD19 target.
Will Multispecific CAR T-Cell Therapy Replace Single-Target CD19 Treatment in Lymphoma?
By Saurabh Dahiya, MD, FACP
CD19-directed CAR T-cell therapy has transformed care for B-cell lymphomas, but most patients still relapse, often due to loss of the CD19 target.
Early-Stage Breast Cancer: Why Fewer Patients Need Chemotherapy, and More Need CDK4/6 Inhibitors
By Ruta Rao, MD
Genomic testing is increasingly identifying which early-stage, hormone receptor-positive breast cancer patients can safely skip chemotherapy, even among some node-positive premenopausal women.
Early-Stage Breast Cancer: Why Fewer Patients Need Chemotherapy, and More Need CDK4/6 Inhibitors
By Ruta Rao, MD
Genomic testing is increasingly identifying which early-stage, hormone receptor-positive breast cancer patients can safely skip chemotherapy, even among some node-positive premenopausal women.
Early-Stage Breast Cancer: Why Fewer Patients Need Chemotherapy, and More Need CDK4/6 Inhibitors
By Ruta Rao, MD
Genomic testing is increasingly identifying which early-stage, hormone receptor-positive breast cancer patients can safely skip chemotherapy, even among some node-positive premenopausal women.
Beyond G12C: KRAS Lung Cancer Is About to Become a Toolkit, Not a Single Target
By Benjamin Herzberg, MD
KRAS G12C is not the only KRAS mutation worth worrying about, and I think that idea is very close to being obsolete.
Beyond G12C: KRAS Lung Cancer Is About to Become a Toolkit, Not a Single Target
By Benjamin Herzberg, MD
KRAS G12C is not the only KRAS mutation worth worrying about, and I think that idea is very close to being obsolete.
Beyond G12C: KRAS Lung Cancer Is About to Become a Toolkit, Not a Single Target
By Benjamin Herzberg, MD
KRAS G12C is not the only KRAS mutation worth worrying about, and I think that idea is very close to being obsolete.
Head and Neck Cancer: New Antibodies After Checkpoint Failure, and Rethinking Immunotherapy Plus Radiation
By Weining Ken Zhen, MD
Developing new strategies for advanced head and neck cancer after checkpoint inhibitor and chemotherapy failures.
Head and Neck Cancer: New Antibodies After Checkpoint Failure, and Rethinking Immunotherapy Plus Radiation
By Weining Ken Zhen, MD
Developing new strategies for advanced head and neck cancer after checkpoint inhibitor and chemotherapy failures.
Head and Neck Cancer: New Antibodies After Checkpoint Failure, and Rethinking Immunotherapy Plus Radiation
By Weining Ken Zhen, MD
Developing new strategies for advanced head and neck cancer after checkpoint inhibitor and chemotherapy failures.
Colorectal Cancer: Exercise Pays Off, Aspirin's Role Stays Murky, Some Can Stop Immunotherapy Early
By Rishi Batra, MD, MBA
Three abstracts from this year's ASCO meeting speak to very different parts of the colorectal cancer journey
Colorectal Cancer: Exercise Pays Off, Aspirin's Role Stays Murky, Some Can Stop Immunotherapy Early
By Rishi Batra, MD, MBA
Three abstracts from this year's ASCO meeting speak to very different parts of the colorectal cancer journey
Colorectal Cancer: Exercise Pays Off, Aspirin's Role Stays Murky, Some Can Stop Immunotherapy Early
By Rishi Batra, MD, MBA
Three abstracts from this year's ASCO meeting speak to very different parts of the colorectal cancer journey
Triple Negative Breast Cancer Gets Real Momentum: What ASCO 2026 Changes for Patients Now
By Amulya Yellala, MD
Triple negative breast cancer has long been described as hard to treat and fast moving, but this year's data, much of it long-term follow-up on treatments already reshaping practice, continues to build real momentum.
Triple Negative Breast Cancer Gets Real Momentum: What ASCO 2026 Changes for Patients Now
By Amulya Yellala, MD
Triple negative breast cancer has long been described as hard to treat and fast moving, but this year's data, much of it long-term follow-up on treatments already reshaping practice, continues to build real momentum.
Triple Negative Breast Cancer Gets Real Momentum: What ASCO 2026 Changes for Patients Now
By Amulya Yellala, MD
Triple negative breast cancer has long been described as hard to treat and fast moving, but this year's data, much of it long-term follow-up on treatments already reshaping practice, continues to build real momentum.